Next Article in Journal
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
Next Article in Special Issue
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Previous Article in Journal
Determinants of the Cancer Drug Funding Process in Canada
Previous Article in Special Issue
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
 
 
Review

Article Versions Notes

Curr. Oncol. 2022, 29(3), 2008-2020; https://doi.org/10.3390/curroncol29030163
Action Date Notes Link
article pdf uploaded. 16 March 2022 14:40 CET Version of Record https://www.mdpi.com/1718-7729/29/3/163/pdf-vor
article xml file uploaded 17 March 2022 03:02 CET Original file -
article xml uploaded. 17 March 2022 03:02 CET Update https://www.mdpi.com/1718-7729/29/3/163/xml
article pdf uploaded. 17 March 2022 03:02 CET Updated version of record https://www.mdpi.com/1718-7729/29/3/163/pdf
article html file updated 17 March 2022 03:03 CET Original file -
article html file updated 1 August 2022 06:02 CEST Update https://www.mdpi.com/1718-7729/29/3/163/html
Back to TopTop